Silvio Garattini. Show Affiliations »
Abstract
Entities: Disease Species
Mesh: See more » Antiviral Agents/economicsAntiviral Agents/therapeutic useCanadaCzech RepublicEuropean UnionHealth Services AccessibilityHealthcare Disparities/economicsHepacivirusHepatitis C/drug therapyHepatitis C/economicsHumansInterferon alpha-2Interferon-alpha/economicsInterferon-alpha/therapeutic usePolyethylene Glycols/economicsPolyethylene Glycols/therapeutic usePrejudiceRecombinant ProteinsRibavirin/economicsRibavirin/therapeutic use
Substances: See more » Antiviral AgentsInterferon alpha-2Interferon-alphaRecombinant ProteinsPolyethylene GlycolsRibavirinpeginterferon alfa-2bpeginterferon alfa-2a
Year: 2008 PMID: 18678432 DOI: 10.1016/j.jhep.2008.07.003
Source DB: PubMed Journal: J Hepatol ISSN: 0168-8278 Impact factor: 25.083